#PhRMA12 Conversations: Dr. Tim Cote

#PhRMA12 Conversations: Dr. Tim Cote

04.04.12 | By Christian Clymer

PhRMA's Annual Meeting is right around the corner. As you've seen in a previous post by our CEO John Castellani, this year's meeting "is appropriately titled 'Making Medicines do More,' and its goal is to better tell the story of America's biopharmaceutical research industry." We are really looking forward to the discussions in the conference rooms and online.

I wanted to get started a little early, though, so I talked to a few people that represent the most important voices in health care - patients. In these interviews, we talked about the role of partnerships, how they would like to challenge the biopharmaceutical industry, and their goals for the future of health care. Their personal experiences made for some very compelling conversations.

My first conversation was with patient advocate Dr. Timothy Cote, M.D. M.P.H, the Chief Medical Officer for the National Organization for Rare Disorders (NORD). NORD is an umbrella organization of about 450 member organizations that represent patients suffering from rare disorders like muscular dystrophy and cystic fibrosis. A rare disorder is defined as a disease that affects fewer than 200,000 Americans. NORD collectively represents the patients, families and caregivers who are advocating for new therapies to combat these rare diseases.

As a passionate advocate for new treatments, Dr. Cote is not shy to say that he wishes PhRMA members would develop more treatments for the patients suffering from more than 7,000 rare diseases. He is encouraged by our progress, including more than 400 new treatments for rare disorders since the passage of the Orphan Drug Act, but would like to see a lot more.

Stay tuned to hear from other patient voices as we lead up to PhRMA's Annual Meeting on April 12.

What major health care issues would you like to see addressed at the PhRMA Annual Meeting this year?

Follow Christian on Twitter @CCatPhRMA

More On PhRMA — powered by PhRMApedia


Cost in Context